Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-01T07:48:12.259Z Has data issue: false hasContentIssue false

Chapter 12 - Therapeutic and Prognostic Applications

Published online by Cambridge University Press:  04 November 2017

By
Sofia Canete-Portillo  and
Mai P. Hoang
Edited by
Mai P. Hoang
Mai P. Hoang
Affiliation:
Harvard Medical School, Boston
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Immunohistochemistry in Diagnostic Dermatopathology , pp. 287 - 295
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Davies, H, Bignell, GR, Cox, C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54.Google Scholar
Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–16.Google Scholar
Sosman, JA, Kim, KB, Schuchter, L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707–14.Google Scholar
Eckhart, L, Bach, J, Ban, J, Tschachler, E. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun 2000;271(3):726–30.CrossRefGoogle ScholarPubMed
Capper, D, Preusser, M, Habel, A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122(1):11–19.Google Scholar
Skorokhod, A, Capper, D, von Deimling, A, Enk, A, Helmbold, P. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012;67(3):488–91.Google Scholar
Long, GV, Wilmott, JS, Capper, D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37(1):61–65.Google Scholar
Lade-Keller, J, Kristensen, LS, Riber-Hansen, R, et al. A role for immunohistochemical detection of BRAFV600E prior to BRAF-inhibitor treatment of malignant melanoma? J Clin Pathol 2013;66(8):723–25.Google Scholar
Boursault, L, Haddad, V, Vergier, B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One 2013;8(8):e70826.Google Scholar
Busam, KJ, Hedvat, C, Pulitzer, M, von Deimling, A Jungbluth, AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013;37(3):413–20.Google Scholar
Routhier, CA, Mochel, MC, Lynch, K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAFV600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013;44(11):2563–70.Google Scholar
Hofman, V, Ilie, M, Long-Mira, E, et al. Usefulness of immunocytochemistry for the detection of of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol 2013;133(5):1378–81.CrossRefGoogle ScholarPubMed
Colomba, E, Hélias-Rodzewicz, Z, Von Deimling, A, et al. Detection of BRAFp.V600E mutations in melanomas:comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013;15(1):94–100.Google Scholar
Menzies, AM, Lum, T, Wilmott, JS, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol 2014;38(3):377–82.Google Scholar
Pearlstein, MV, Zedek, DC, Ollila, DW, et al. Validation of the VE1 immunostain for the BRAFV600E mutation in melanoma. J Cutan Pathol 2014;41(9):724–32.Google Scholar
Ihle, MA, Fassunke, J, Konig, K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014;14(13):13. doi: 10.1186/1471-2407-14-13.Google Scholar
Kakavand, H, Walker, E, Lum, T, et al. BRAF (V600E) and NRAS (Q61 L/Q61 R) mutational analysis in metastatic melanoma using immunohistochemistry: A study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology 2016;69(4):680–86.Google Scholar
Schirosi, L, Strippoli, S, Gaudio, F, et al. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? BMC Cancer 2016;16:905.Google Scholar
Kwong, LN, Costello, JC, Liu, H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012;18(10):1503–10.Google Scholar
Jakob, JA, Bassett, RL Jr, Ng, CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014–23.Google Scholar
Nazarian, R, Shi, H, Wang, Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2000;468(7326):973–77.Google Scholar
Ascierto, PA, Schadendorf, D, Berking, C, et al. MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: A non-randomized, open-label phase 2 study. Lancet Oncol 2013;14(3):249–56.Google Scholar
Massi, D, Simi, L, Sensi, E, et al. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61 R mutation in melanoma. Mod Pathol 2015;28(4):487–97.Google Scholar
Ilie, M, Long-Mira, E, Funck-Brentano, E, et al. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61 R mutation in patients with metastatic melanoma. J Am Acad Dermatol 2015;72(5):786–93.Google Scholar
Uquen, A, Guequen, P, Legoupil, D, et al. Dual NRASQ61 R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Hum Pathol 2015;46(11):1582–91.Google Scholar
Dias-Santagata, D, Su, Y, Hoang, MP. Immunohistochemical detection of NRASQ61 R mutation in diverse tumor types. Am J Clin Pathol 2016;145(1):29–34.Google Scholar
Curtin, JA, Busam, K, Pinkel, D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4360–66.Google Scholar
Torres-Cabala, CA, Lang, WL, Trent, J, et al. Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22(11):1446–56.Google Scholar
Beadling, C, Jacobson-Dunlop, E, Hodi, FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821–28.Google Scholar
Carvajal, RD, Antonescu, CR Wolchok, JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305(22);2327–34.Google Scholar
Hodi, FS, Friedlander, P, Corless, CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26(12):2046–51.Google Scholar
Allegra, M, Giacchero, D, Segalen, C, et al. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol 2014;134(5):1473–76.Google Scholar
Dai, B, Cai, X, Kong, YY, et al. Analysis of KIT expression and gene mutation in human acral melanoma: With a comparison between primary tumors and corresponding metastases/recurrences. Hum Pathol 2013;44(8):1472–78.Google Scholar
Ni, S, Huang, D, Chen, X, et al. C-KIT gene mutation and CD117 expression in human anorectal melanomas. Hum Pathol 2012;43(6):801–7.Google Scholar
Santi, R, Simi, L, Fucci, R, et al. KIT genetic alterations in anorectal melanomas. J Clin Pathol 2015;68(2):130–34.Google Scholar
Hapgood, G, Savage, KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood 2015;126(1):17–25.Google Scholar
Drexler, HG, Gignac, SM, von Wasielewski, R, Werner, M, Dirks, WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000;14(9):1533–59.Google Scholar
Ceccon, M, Mologni, L, Giudici, G, et al. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol Cancer Res 2015;13(4):775–83.CrossRefGoogle ScholarPubMed
Busam, KJ, Kutzner, H, Cerroni, L, Wiesner, T. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. Am J Surg Pathol 2014;38(7):925–33.Google Scholar
Weisner, T, He, J, Yelensky, R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014;5:3116. doi: 10.1038/ncomms4116.Google Scholar
Yeh, I, de la Fouchardiere, A, Pissaloux, D, et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol 2015;39(5):581–91.Google Scholar
Shiota, M, Fujimoto, J, Takenaga, M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994;84():3648–52.Google Scholar
Lamant, L, Meggetto, F, al Saati, T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin’s disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and p-80 immunostaining. Blood 1996;87(1):284–91.Google Scholar
Pulford, K, Lamant, L, Morris, SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89(4):1394–404.Google Scholar
Selinger, CI, Rogers, TM, Russell, PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26(12):1545–53.Google Scholar
Weisner, T, He, J, Yelensky, R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014;5:3116. doi: 10.1038/ncomms4116.Google Scholar
Yoshida, A, Tsuta, K, Wakai, S, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 2014;27(5):711–20.Google Scholar
Takeuchi, K, Soda, M, Togashi, Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18(3):378–81.Google Scholar
Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371(21):1963–71.Google Scholar
Su, Y, Goncalves, T, Dias-Santagata, D, Hoang, MP. Immunohistochemical detection of ROS1 gene fusion. Am J Clin Pathol 2017;147(3):77–82.Google Scholar
Sholl, LM, Sun, H, Butaney, M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013;37(9):1441–49.Google Scholar
Tanaka, R, Sasajima, Y, Tsuda, H, et al. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol 2013;168(6):1259–66.Google Scholar
Diaz de Leon, E Carcanqiu, ML, Prieto, VG, et al. Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor. Am J Clin Pathol 2000;113(4):572–75.Google Scholar
Hanawa, F, Inozume, T, Harada, K, et al. A case of metastatic extramammary Paget’s disease responding to trastuzumab plus paclitaxel combination therapy. Case Rep Dermatol 2011;3(3):223–27.CrossRefGoogle ScholarPubMed
Takahagi, S, Noda, H, Kamegashira, A, et al. Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol 2009;36(8):457–61.Google Scholar
Le, LP, Dias-Santagata, D, Pawlak, AC, et al. Apocrine-eccrine carcinomas: Molecular and immunohistochemical analyses. PLoS One 2012;7(10):e47290.Google Scholar
Battistella, M, Mateus, C, Lassau, N, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal caricnomas: Report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol 2010;24(2):199–203.Google Scholar
Schroder, U, Dries, V, Klussmann, JP, Wittekindt, C, Eckel, HE. Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma: Need for a clinical trial? Ann Otol Rhinol Laryngol 2004;113(3 Pt 1):242–44.Google Scholar
Ogawa, T, Nagashima, Y, Wada, H, et al. Extramammary Paget’s disease: Analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Hum Pathol 2005;36(12):1273–80.Google Scholar
Reich, O, Liegl, B, Tamussino, K, Regauer, S. p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget’s disease. Mod Pathol 2005;18(3):354–57.Google Scholar
Tanaka, R, Sasajima, Y, Tsuda, H, et al. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clin Exp Metastasis 2016;33(7):687–97.Google Scholar
Maloney, DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366(21):2008–16.Google Scholar
Morales, AV, Advani, R, Horwitz, SM, et al. Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. J Am Acad Dermatol 2008;59(6):953–57.Google Scholar
Valencak, J, Weihsengruber, F, Rappersberger, K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients. Ann Oncol 2009;20(2):326–30.Google Scholar
Zou, W, Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467–77.Google Scholar
Topalian, SL, Hodi, FS, Brahmer, JR, et al. Safety, activity, and immune correlates of anti-PD1 antibody in cancer. N Engl J Med 2012;366(26):2443–54.Google Scholar
Hamid, O, Robert, C, Daud, A, et al. Safety and tumor responses with Lambrolizumab (anti-PD1) in melanoma. N Engl J Med 2013;369(2):134–44.Google Scholar
Kakavand, H, Vilain, RE, Wilmott, JS, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015;28(12):1535–44.Google Scholar
Madore, J, Vilain, RE, Menzies, AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28(3):245–53.Google Scholar
Jacobs, JF, Nierkens, S, Figdor, CG, de Vries, IJ, Adema, GJ. Regulatory T-cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol 2012;13(1):e32–42.CrossRefGoogle ScholarPubMed
Yu, Y, Huang, R, Zong, X, He, X, Mo, W. INFα-2b inhibitory effects on CD4(+) CD25(+) FOXP3(+) regulatory T-cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts. BMC Cancer 2016;16:397. doi: 10.1186/s12885-016-2473-0.Google Scholar
Leslie, C, Bowyer, SE, White, A, et al. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology 2015;47(6):557–63.Google Scholar
Bielekova, B, Richert, N, Howard, T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U.S.A. 2004;101(23):8705–8.Google Scholar
Martin, R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012;142(1):9–14.Google Scholar
Powell, DJ Jr, Felipe-Silva, A, Merino, MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T-cells in vivo. J Immunol 2007;179(7):4919–28.Google Scholar
Rosenberg, SA Yannelli, JR, Yang, JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86(15):1159–66.Google Scholar
Tumeh, PC, Harview, CL, Yearley, JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568–71.Google Scholar
Kakavand, H, Vilain, RE, Wilmott, JS, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015;28(12):1535–44.Google Scholar
Gerber, AL, Munst, A, Schlapbach, C, et al. High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol 2014;170(1):103–9.CrossRefGoogle ScholarPubMed
Gooden, MJ, de Bock, GH, Leffers, N, Daemen, T, Nijman, HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 2011;105(1):93–103.Google Scholar
Harcharik, S, Bernardo, S, Moskalenko, M, et al. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II and –III cutaneous melanoma. J Am Acad Dermatol 2014;70(6):1036–44.Google Scholar
Galon, J, Mlecnik, B, Bindea, G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014;232(2):199–209.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×